Dr. Declan Doogan serves as Director & Chief Executive Officer at Portage Biotech. He is a Co-Founder and serves as Partner at MediqVentures. He also serves as Board Member at Intensity Therapeutics. He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.
David Lowe
Investing in Software (Web Marketplace Saas..) &b...
San Francisco Califor..., Canada
Previous Investments
• Shattuck Labs:
$46620000 (Later stage VC)
David Lowe
San Francisco California - Waltham Massachusetts - Walnut California - - Texas - Toronto Ontario Canada - Ontario Canada, Canada
Dr. David Lowe is a Co-Founder of Aeglea BioTherapeutics Holdings. He also served as Chief Executive Officer at Aeglea BioTherapeutics. He is a Board Member at Shattuck Labs. He is a Board Member at MaRS Innovation.. Previously, he srved as managing director at Skyline Ventures. Dr. Lowe joined Skyline Ventures in 2002 and became a partner at Skyline in 2003. Prior to joining Skyline, Dr. Lowe was employed at Genentech, a biotherapeutics company, from 1985 to 2001, where he led drug discovery activities in biologics and small molecule therapeutics. Dr. Lowe held various positions while at Genentech including Director of Cardiovascular Research. Dr. Lowe currently serves on the Boards of Directors of Applied Genetics Technologies Corporation, Proteon Therapeutics, and ARCA Discovery. Dr. Lowe holds B.S. and Ph.D. degrees in biochemistry from the University of Toronto, Canada
Roxanne Varza
Investing in Software (Web Marketplace Saas..) &b...
Roxanne Varza is currently Director of STATION F, the biggest startup campus in the world with more than 1,000 startups, located in Paris. She is also an angel investor (companies include Claap, Folk, Resilience.care, Moka.care, Colette and more) and scout for Sequoia Capital (and was previously a scout at Atomico).Before joining STATION F, sheled Microsoft Ventures Paris and was Editor of TechCrunch France. She also worked for several London-based startups and cofounded StarHer (now part of SISTA), Tech.eu and Failcon France. She has also been a member of the French Government's Conseil National du Numérique (CNNum) and the European Commission's European Innovation Council (EIC).Roxanne is trilingual and holds degrees from UCLA, Sciences Po Paris and the London School of Economics.
Ilya Nykin
Investing in Software (Web Marketplace Saas..) &b...
Thomas Clozel co-founded Owkin with Gilles Wainrib and serves as Chief Executive Officer. Mr. Clozel attended Weill Medical College of Cornell University and Icahn School of Medicine at Mount Sinai.
How to connect with Angel Investors in the Oncology industry?
In the Oncology industry, angel investors such as Vinod Khosla, Esther Dyson, and Steve Jurvetson are highly active. These investors focus on startups offering innovative solutions in cancer treatment, diagnostics, and research. Vinod Khosla, founder of Khosla Ventures, invests in oncology startups that have the potential to significantly advance cancer care and treatment outcomes. Esther Dyson, an entrepreneur and investor, looks for companies that leverage technology to improve cancer diagnostics and patient care. Steve Jurvetson, a co-founder of Future Ventures, seeks out startups with strong scientific foundations and impactful oncology solutions. To connect with these investors, attend oncology conferences, medical expos, and networking events such as ASCO Annual Meeting, World Cancer Congress, and AACR Annual Meeting. Utilize platforms like AngelList and LinkedIn to identify and reach out to potential investors. When pitching, emphasize how your oncology solution addresses key challenges, such as improving cancer diagnostics, enhancing treatment efficacy, or advancing research. Highlight any traction you’ve gained, such as partnerships with medical institutions, successful clinical trials, or regulatory approvals. Building relationships through initial informal meetings or discussions at industry panels can help establish trust with these investors. Demonstrating the impact of your technology through case studies or clinical results can also add credibility. Personalize your outreach by referencing the investor’s previous investments and explaining how your venture aligns with their interests. Demonstrating a sustainable business model with clear revenue streams, such as product sales, licensing, or research grants, will further strengthen your pitch. Leveraging endorsements or case studies from oncology experts can also enhance your credibility.
Case Studies: Successful Funding Rounds with Angel Investors on Angels Partners
Exotic Orange & Angels Partners: Turning Financial Simplicity Into Investment Success
